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Abstract Consecutive adultpatients (n=70) referred forinvestigationof suspectedasthmawerereinvestigatedafter 5
years with the same diagnostic procedures (airway symptom score, spirometry, methacholine test) as used at the initial
investigation.The same diagnostic criteria for asthma, asthma-like disorder (current asthma-like symptomsbutnegative
asthmatests) andchronicobstructivepulmonarydisease (COPD)wereusedatbothvisits.Atthe first visit 39/70 patients
(56%) fulfilled the asthma criteria, 21/70 (27%) fulfilled the asthma-like criteria and 5/70 (7%) the COPDcriteria.Due to
lackof current symptoms 5/70 (7%) could not be classified. 5/70 patients (7%) were smokers, however, in themajority
(72%) smoke was not tolerated as it induced asthma-like symptoms. At the investigation, 5 years later, 30/39 patients
(76%) still fulfilled the asthma criteria and12/21patients (57%) still fulfilled the asthma-like criteria. Atthe 5-year investi-
gation,10% of patients in the asthma group now fulfilled the asthma-like criteria and10% of patients in the asthma-like
group fulfilled the asthma criteria.It is concluded that asthma aswell an asthma-like syndromemaypersist for 5 years or
more.It is also concludedthatthetwo disorders are closelyrelated aspatientsinthe asthmagroup over time couldmove
into the diagnostic criteria ofthe asthma-like disorder and vice versa.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.comon
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Asthma is de¢ned as a disorder with bronchial in£amma-
tion, reversible bronchial obstruction and bronchial hy-
perreactivity. The diagnostic criteria have been
established in international consensus reports (1^4). In
an asthma and allergy clinic, it has frequently been ob-
served that some patients present asthma-like symp-
toms (breathlessness, di⁄culty in getting air, cough,
etc.) but, despite severe symptoms, have no reversibility
to a b2-agonist or bronchial hyperreactivity asmeasured
by a methacholine test. The question has been raised
whether these patients have a latent or a mild asthma
that may progress into a manifest asthma or whether
this disorder is another type of asthma, as asthma-like
symptoms associated with subjective hyperreactivity
(5^11) and sensory hyperreactivity have been described
(12,13).
The aim of this study was to systematically investigate
consecutively included patients with lower airway pro-Received19 March 2002
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E-mail: olle.lowhagen@lungall.gu.seblems and after 5 years to reinvestigate these patients
with the same diagnostic criteria and procedures in or-
der to analyse changes in diagnoses and values of diag-
nostic parameters used (symptoms, bronchial
obstruction, reversibility, hyperreactivity).
PATIENTSANDMETHODS
The study included 70 patients, 53 women and 17 men.
The mean age was 41years, with a range of17^67 years.
All patients were referred to our outpatient clinic for in-
vestigation of suspected asthma and were consecutively
included in the study.None of the patients had visited an
asthma specialist before. The duration of the airway
symptoms varied between 1 and 48 years, with a mean
of 9 years. Before admission, 62 patients (89%) had been
prescribed b2-stimulants by inhalation and of these, 12
(19%) reported no e¡ect. Inhaled steroids had been pre-
scribed in 34 patients (49%). Exact e⁄cacy could not be
assessed, as the drug compliance was low.The investiga-
tion involved physical examination, questionnaire for as-
sessment of airway symptoms and symptoms induced by
trigger factors, FEV1 with b2-reversibility, diurnal varia-
tion in PEF (peakexpiratory £owrate)withb2-reversibil-
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tions were repeated in exactly the sameway.
Questionnaire
The questionnaire included 26 common respiratory/
chest symptoms, such as wheezing, heavy breathing,
tightness, cough, secretion, etc. Each patient graded the
frequency of symptoms on a scale from 0 to 3 (0 = never,
1 = sometimes, 2 = often, 3 = daily symptoms). Ques-
tions had the following formula: ‘How often do you ex-
perience wheezing?’ The severity of symptoms from 12
common trigger factors F cold air, exercise, tobacco
smoke, perfumes, exhaust gases, chemicals, £ower
scents, etc.F were also scored 0^3 (0 = no,1 = mild, 2
= moderate and 3 = severe symptoms).These questions
followed this formula: ‘What degree of breathing pro-
blems do you experience when you are running?’,‘What
degree of breathing trouble do you experience fromper-
fumes?’ In order to be classi¢ed as ‘positive’ (current
symptoms) a symptom score2 was required.
Airway function tests
FEV1was measured before and after 0.8mg inhaled sal-
butamol. Two reproducible forced expiration curves
were required each time. Short- and long-acting bronch-
odilators were not allowed within 4 and 12h before the
test, respectively. Peak expiratory £ow rate (PEF) was
measuredmorning and night before and after 0.8mg in-
haled salbutamol over a period of14 days.The best value
of two was noted on a special protocol. The patients
were instructed not to take other short- or long-acting
bronchodilators during this period. Mean morning and
mean night values were expressed as percentage of pre-
dicted value.The reversibility was expressed as the per-
centage change of thepre-b2-value.Variabilityduring the
period was expressed as the percentage di¡erence be-
tween the lowest PEF (morning before the b2-agonist)
and the highest value (evening after the b2-agonist) (3).
Methacholine test
Amethacholine testwas performed according to a stan-
dardised method (14,15). Neither short- nor long-acting
bronchodilators were allowed within 4 and12h, respec-
tively, before the test.Thepatient inhaledNaCl (starting
volume 2ml) for 2min, with the FEV1value afterNaCl as
the baseline.This value should be at least 65% of the ex-
pected value. Two-fold increasing doses were given by
doubling the concentration of methacholine starting
with 0.03mg/ml.The interval between doses was 5min.
FEV1 was recorded 2 and 4min after the end of each
dose.The test was terminated when the fall in FEV1was
more than 20%, or when the maximum dose (16mg/ml)was reached.The threshold dosewhich gave a fall in FEV1
20% (a value slightly higher than corresponding PC20-
value) was used.The limit for a positive response was a
threshold doseo4mg/ml.
Skin-prick test (SPT)
STP was performed with 12 common inhalant allergens:
house dust mite, mould, cat, dog, horse and pollen
(birch, grass and mugwort).The weals were graded tra-
ditionally in a plus system in relation to theweal of hista-
minewhichwas set to 3+.
Medication
After the investigation medication was changed and
adapted to the current severity of the disease.For an ap-
proximate comparison of medication (b2-agonists and
inhaled steroids) between the twovisits a stepwise grad-
ing (0^4) was used according the following: (0) no asth-
ma medication; (1) bronchodilators as required; (2)
addition of inhaled steroids up to 1000mg/day; (3) addi-
tion of inhaled steroids 41000mg/day; and (4) addition
of oral steroids.The inhaled steroids used (beclometha-
sone and budesonide) were considered equipotent.
Long-acting b2-agonists and leucotriene inhibitors could
not be compared, as they were not generally used at the
time of the initial investigation. For practical and ethical
reasons a complete control of compliance andprescribed
medication made by di¡erent physicians could not be
conducted during the observation period.
Diagnostic criteria
For the diagnosis of asthma the following two criteria
should be ful¢lled: (1) airway symptoms (wheezing,
breathing trouble, cough or phlegm) graded 2 in the
questionnaire; and (2) at least one of the following:
10% increase of mean morning PEF, 10% increase in
FEV1after 0.8mg inhaled salbutamol, or a threshold dose
of methacholineo4mg/ml. For an asthma-like disorder
the following criteria shouldbe ful¢lled: (1) Airway symp-
toms (wheezing, breathing trouble, cough or phlegm)
graded 2; (2)o10% increase of mean morning PEF or
o10% increase in FEV1after 0.8mginhaled salbutamol or
a threshold dose of methacholine 4mg/ml; and (3)
meanmorning PEF or FEV180% predicted (for exclud-
ing a non-reversible bronchial obstruction such as
COPD).
Statisticalmethods
Standardmethods were used for calculation of mean, SD
and correlation coe⁄cient (r). Di¡erences between
1042 RESPIRATORYMEDICINEgroups were analysed with non-parametric tests. For
statistical signi¢cance a P-value ofo0.05 was required.
RESULTS
Drop out
In the initial study (year 0) all patients carried out the in-
vestigations. At year 5, six patients failed to attend the
clinical investigation, three were not willing to partici-
pate and three had moved far away. Three patients in
year 0 and eight patients in year 5 were not willing to
have a methacholine test.
Diagnoses year 0
Of the 70 patients 39 (56%) ful¢lled the criteria for asth-
ma and 21 (27%) ful¢lled the criteria for asthma-like dis-
order. Five patients (7%) had a PEF or FEV1 o80%
predicted and reversibility o10% (COPD-like group).
All ¢ve were non-smokers. An additional ¢ve patients
(7%) could not be classi¢ed due to lack of data or symp-
toms (symptom score o2). Seventy-two percent of all
patients reported airway symptoms to smoke (symptom
score2).
Diagnoses year 5
Of 70 patients, 35 (50%) ful¢lled the criteria for asthma
and19 (29%) ful¢lled criteria for asthma-like disorder.Of
the remaining patients two (3%) had a non-reversible
bronchial obstruction (COPD-like group) and 14 (20%)
could not be classi¢ed. Seven did not attend and seven
did not report enough symptoms.
Changes in diagnoses fromyear 0 to year 5
At the 5-year investigation, 30/39 patients (76%) in the
asthma group fromyear 0 still ful¢lled the asthma criter-
ia. Four patients (10%) had moved into the criteria of an
asthma-like disorder, two (8%) had moved into the
COPD-like group, and three (8%) could not be classi¢ed.
After 5 years, 12/21 patients (57%) in the asthma-like
group still ful¢lled the same criteria, 2/21 (10%) now ful-
¢lled the asthma criteria, and 7/21 (33%) could not be
classi¢ed (no symptoms or no attendance). Of the ¢ve
COPD-like patients at year 0, two now ful¢lled the asth-
ma criteria and two the asthma-like criteria. In total, at
the 5-year investigation, 35/70 patients (50%) ful¢lled
the asthma criteria, 19/70 (27%) ful¢lled the asthma-like
criteria, 2/70 (3%) were COPD-like, and14/70 could not
be classi¢ed due to lack of data (n = 9) or not enough
symptoms (n = 5).Skin-prick test
Of the 39/70 patients who ful¢lled asthma criteria, 13
(33%) had a positive SPT.Of the 21/70 patients who ful-
¢lled the criteria for an asthma-like disorder, 9 (43%)
had a positive skin-prick test.
Medication
After the initial investigation, 29/39 patients (74%) in the
asthma group, and 4/21patients (19%) in the asthma-like
group were prescribed (in addition to a bronchodilator)
inhaled steroids in a dose 1000mg/day. None was pre-
scribed a higher dose or an oral steroid on a daily basis.
After the 5-year investigation, 25/39 patients in the asth-
ma group (64%), and 6/21 patients (29%) in the asthma-
like group were prescribed inhaled steroids. Five out of
39 patients (13%) in the asthma group but none in the
asthma-like group were prescribed a dose 41000mg/
day.Nonewas prescribed an oral steroid on a regular ba-
sis.Ten out of 39 patients in the asthma group, and 9/21in
the asthma-like group only had an inhaled b2-agonist
when needed.
DISCUSSION
In this study, we believe that three important observa-
tions havebeenmade.The ¢rst is thatpatientswith asth-
ma or asthma-like symptoms of similar severitymayhave
asthma or an asthma-like disorder, which may not be
classi¢ed as COPD or a healthy stage.The second obser-
vation is that this disorder may persist for 5 years or
more.The third is that asthma and the asthma-like disor-
der may be closely related, as asthma in some patients
moved over time into the diagnostic criteria of the asth-
ma-like disorder and vice versa. As asthma and asthma-
like disorders appear to be so closely related, the most
important conclusion is that asthma-like disorders must
be considered in future asthma studies. In both diseases
there are asthma-like symptoms, but the asthma-likedis-
orders must be separated by the absence of bronchial
obstruction and bronchial hyperresponsiveness. How-
ever, separation of two disordersmaybe di⁄cult in some
cases as the two disorders (ormechanisms) may be pre-
sent in the same patient.The observation that the asth-
ma-like disorder persisted for at least 5 years does not
support the hypothesis that this disorder is a pre-stage
to asthma. It could also be the other way around, as
somepatients in the asthmagroupmovedinto the criter-
ia for an asthma-like disorder.The number of patients in
this initial observational study is limited, and a study with
a larger number of patients during even longer period of
timemay therefore be important.
Although in each study patient was referred for the
investigation of suspected asthma, the participants are
not representative of all types of patients with asthma
ASTHMA ANDASTHMA-LIKEDISORDER 1043and asthma-like symptoms. However, they were conse-
cutively included in the investigation and may represent
patients with more severe disease and patients in whom
the diagnosis of asthma has been problematic.The diag-
nostic criteria chosen are in accordance with recent
guidelines (1^4) where it is stressed that diagnosis of
asthma should be based on the presence of episodic air-
way symptoms and reversible air£ow obstruction and
the exclusion of alternative diagnoses. However, the ex-
act values for a ‘positive’ result are crucial and are not gi-
ven for all diagnostic parameters in the consensus
reports, with two exceptions, reversibility to a b2-ago-
nist12% (3) and PEF-variability420% (3). Di¡erent di-
agnostic criteriawith di¡erentvalues for a positive result
have been used in various studies and, as in this study,
they may be discussed. However, even if the diagnostic
procedures and the values for a positive result in this
studyhadbeen chosen in a slightlydi¡erentway themain
result of the two key groups would have been the same.
As in all clinical follow-up studies the in£uence ofmed-
ication on the diagnostic methods may be considered,
especially of steroids, as they may reduce bronchial hy-
perresponsiveness and improve lung function.For ethical
reasons, treatmentmust always be given and a complete
control during a long period of time is not easy to per-
form.Mostpatients in the asthmagroupwereprescribed
inhaled steroids compared to only a few in the asthma-
like group. An improvement in the mean values of lung
function, reversibility and hyperresponsiveness was also
seen in the asthma group (Table1), and it may be specu-
lated that patients in this groupmay havemoved into the
criteria of an asthma-like disorder due to positive e¡ects
of treatment. However, only 10% of the asthma group
moved thatway and themajority still ful¢lled the asthma
criteria after 5 years.Thepossibilityof normalising or im-
proving lung function and hyperresponsiveness by asth-
ma treatment underlines the need for a careful
registration of airway symptoms and trigger factors asTABLE 1. Lung function andhyperreactivity.Lung function data
at years 0 and 5 inthe same patients
All
Year 0 (mean, range)
FEV1% pred. 98 (29^137)
FEV1% revers. 8 (4 to 59)
PEF % pred. 82 (49^114)
PEF% revers. 13 (5 to 53)
Methacholine (median) 2.0 (0.06^16.0)
Year 5 (mean, range)
FEV1% pred. 93 (33^120)
FEV1% revers. 6 (13^26)
PEF % pred. 90 (32^137)
PEF% revers. 10 (0^65)
Methacholine (median) 4.0 (0.03^16.0)there are yet few other diagnostic parameters available
(23).
Asthma-like symptoms not directly related to bron-
chial obstruction have been discussed only sparingly in
recent consensus reports (1^4). In other literature there
is an increasing use of the term ‘asthma-like’ which may
indicate a growing awareness of the existence of asth-
ma-like symptoms not directly related to reversible air-
way obstruction. However, there seems to be no
previous study in adults where the diagnoses of asthma
and asthma-like disorders have been critically compared
and reinvestigated after a certain period of time. In a re-
centconsensus some di¡erential diagnoses in adults, such
as COPD, laryngeal dysfunction, cough secondary to
drugs, and vocal cord dysfunction are listed (3), but none
of these seems to be similar to the asthma-like disorder
found in this study. COPD due to smoking is often re-
ported as a commondi¡erential diagnosis.Nevertheless,
in this study, carried out in an asthma and allergy clinic,
signs of a non-reversible bronchial obstruction were
found in only a few patients, all of whomwere non-smo-
kers. In patients with asthma-like cough and secretion
chronic bronchitis is a di¡erential diagnosis. However,
chronic bronchitis, when not due to smoking, may be a
non-speci¢c disorder. In this study only ¢ve patients
(7%) were smokers and in the majority of the patients
(72%) smokewas not tolerated as it induced asthma-like
symptoms. For studying mechanisms and aetiology in
these cases, we think it is more fruitful to focus on type
of airway symptoms, trigger factors andbronchial hyper-
reactivity.
Other disorders with asthma-like symptoms have
beendescribed, including thehyperventilation syndrome
(16^18),‘ski asthma’ (19,20) andmultiple chemical sensitiv-
ity (21,22). It is possible that some of our patients could
have these disorders, but the study was not designed to
answer such questions. It is also likely that some of our
patients may have a sensory hyperrreactivity (12,15), as(mean, range) andmethacholine test (threshold dose, median)
Asthma Asthma-like
91 (29^134) 110 (95^137)
12 (0^59) 4 (0^8)
76 (49^109) 95 (82^114)
19 (3^53) 4 (5 to 9)
0.5 (0.06^16.0) 8.0 (4.0^16.0)
88 (54^117) 106 (93^120)
8 (13^26) 3 (0^8)
87 (32^123) 99 (74^137)
11 (0^56) 6 (2^15)
1.0 (0.03^16.0) 8.0 (1.0^16.0)
1044 RESPIRATORYMEDICINEcough and breathing troubles induced by odours were
reported amongmany of them.Capsaicin, a stimulant of
sensorynerves, is used toverify a sensoryhyperrreactiv-
ity (12),but the testwasnotinuseat thestartof this study.
As pointed out above, even if the inclusion criteria had
been selected or combined in a di¡erent way the main
results for the two patient groups would have been the
same. For example, if a positive reversibility in FEV1was
set to12%, onlyone of thepatients in the asthma group
wouldbe classi¢ed as non-asthma (moving into the asth-
ma-like group). If a PEF variability 20% had been in-
cluded in the diagnostic criteria for asthma, only one
asthma patientwouldhavebeen classi¢ed as non-asthma
(moving into the asthma-like group). As bronchial ob-
struction and b-reversibility are key points in the clinical
diagnostics of asthma (1^4), we consistently measured
PEF during a 2-week period before and after a b2-ago-
nist. A mean morning reversibility of 10% was chosen as
the limit for a positive result since good correlationwith
the FEV1-reversibility had been found in earlier pilot stu-
dies. If the methacholine test had been excluded as a di-
agnostic test, the subdivision of the two main groups
would have been similar. The methacholine test may be
positive for disorders other than asthma but a negative
test may strongly exclude asthma (3,6,8,15). For this rea-
son, the test may be valuable when separating asthma
from an asthma-like disorder. In consensus reports the
presence of symptoms has been stressed (2^4). All pa-
tients in the present study had current episodic airway
symptoms at the initial investigation, but after 5 years,
¢ve patients no longer had symptoms according to the
initial criteria. The severity of symptoms in the two
groupswas not exactly compared as only the lower limit
for symptom score was determined. Measuring symp-
toms is not an easy task as there are many di¡erent air-
way symptoms, such as wheezing, cough, secretion,
breathing troubles, chest tightness, symptoms at night,
symptoms induced by di¡erent trigger factors, etc.
Which are most speci¢c for asthma? Extensive studies
of airway symptoms thatmaybe associatedwith asthma
and asthma-like disorders, respectively, are now in pro-
gress (23).
From the observations made in this follow-up study
we conclude that some patients with asthma-like symp-
toms may not have asthma, COPD or a healthy state.
Our ¢rst hypothesis is that there are one or more asth-
ma-like disorders, such as sensory hyperreactivity, that
must be seriously considered in future clinical studies of
asthma. Our second hypothesis is that these disorders
may be common and may clinically, although not fatal,
be as severe as ‘classical’ asthma.
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